Abstract
Cardiovascular diseases differ between men and women as do outcomes after therapeutic interventions. Management of these diseases, however, is generally guided by evidence from trials conducted predominantly in men, with few studies focused on women alone. Our goal is to review the sex/gender differences in cardiovascular therapies, which show many areas of uncertainty regarding women due to their small enrolment in clinical trials; thus, in some cases, firm conclusions about efficacy in women are difficult to obtain. Nevertheless, female gender appears to suffer from more adverse drug effects (ADE) than the male gender. For example, women are significantly more likely to experience drug-induced QT-prolongation and torsade de pointes arrhythmia and many other types of ADE. The major sex-specific differences present in pharmacokinetics, especially for the major drug metabolizing enzymes, the cytochromes P450 family, but also for phase II reactions such as glucuronidation, are discussed. Pharmacodynamic mechanisms underlying sex/gender differences are not clearly elucidated yet; however, this highlights the need for more studies focusing on women in order to optimize sex/gender-specific therapy and, therefore, improve clinical outcomes in women with cardiovascular diseases.
Keywords: Sex/gender differences, cardiovascular system, pharmacokinetics, pharmacodynamics, drug adverse effects, pathology, oestrogens, polytherapy, dimorphic, gastrointestinal, microvasculature, creatinine, ventilatory, biotransformation, sulfotransferases, glutathione-S, epigenetic
Current Pharmaceutical Design
Title: The Effect of SEX/Gender on Cardiovascular Pharmacology
Volume: 17 Issue: 11
Author(s): Flavia Franconi, Ciriaco Carru, Walter Malorni, Stefano Vella and Giuseppe Mercuro
Affiliation:
Keywords: Sex/gender differences, cardiovascular system, pharmacokinetics, pharmacodynamics, drug adverse effects, pathology, oestrogens, polytherapy, dimorphic, gastrointestinal, microvasculature, creatinine, ventilatory, biotransformation, sulfotransferases, glutathione-S, epigenetic
Abstract: Cardiovascular diseases differ between men and women as do outcomes after therapeutic interventions. Management of these diseases, however, is generally guided by evidence from trials conducted predominantly in men, with few studies focused on women alone. Our goal is to review the sex/gender differences in cardiovascular therapies, which show many areas of uncertainty regarding women due to their small enrolment in clinical trials; thus, in some cases, firm conclusions about efficacy in women are difficult to obtain. Nevertheless, female gender appears to suffer from more adverse drug effects (ADE) than the male gender. For example, women are significantly more likely to experience drug-induced QT-prolongation and torsade de pointes arrhythmia and many other types of ADE. The major sex-specific differences present in pharmacokinetics, especially for the major drug metabolizing enzymes, the cytochromes P450 family, but also for phase II reactions such as glucuronidation, are discussed. Pharmacodynamic mechanisms underlying sex/gender differences are not clearly elucidated yet; however, this highlights the need for more studies focusing on women in order to optimize sex/gender-specific therapy and, therefore, improve clinical outcomes in women with cardiovascular diseases.
Export Options
About this article
Cite this article as:
Franconi Flavia, Carru Ciriaco, Malorni Walter, Vella Stefano and Mercuro Giuseppe, The Effect of SEX/Gender on Cardiovascular Pharmacology, Current Pharmaceutical Design 2011; 17 (11) . https://dx.doi.org/10.2174/138161211795656918
DOI https://dx.doi.org/10.2174/138161211795656918 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Many Antithrombotic Actions of Nitric Oxide
Current Drug Targets From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Lipid Management and Peripheral Arterial Disease
Current Drug Targets Editorial (Thematic Issue: New Therapeutic Targets in Clinical Medicine)
Current Pharmaceutical Design Modulation of Ion Channels in Pulmonary Arterial Hypertension
Current Pharmaceutical Design Analysis of Current Antifungal Agents and Their Targets within the Pneumocystis carinii Genome
Current Drug Targets Syphilis: An Epidemiological Review
Current Women`s Health Reviews Editorial from Guest Editors [Hot Topic: Viral Bronchiolitis: The Year in Review (Guest Editors: Louis Bont and Jan Kimpen)]
Current Respiratory Medicine Reviews The Coronary Circulation in Cyanotic Congenital Heart Disease
Current Cardiology Reviews Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Recent Advances in the Synthesis of 1,3-Azoles
Current Topics in Medicinal Chemistry Clinical Thiazolidinediones as PPARγ Ligands with the Potential for the Prevention of Cardiovascular Disease in Diabetes
Current Diabetes Reviews Application of Proteomics in Cardiovascular Research
Current Proteomics Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Effect of Hyperthermia and Triblock Copolymeric Nanoparticles as Quercetin Carrier on DU145 Prostate Cancer Cells
Current Nanoscience Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?)
Current Vascular Pharmacology Development and Characterization of Spray Dried Microparticles for Pulmonary Delivery of Antifungal Drug
Current Drug Delivery Troponin in Newborns and Pediatric Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry State-of-the-Art Review of Current Therapies for HFpEF: An Overview of Interatrial Septal Device Therapy in Heart Failure
Current Cardiology Reviews